Last reviewed · How we verify
rondecabtagene autoleucel
Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells.
Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells. Used for Metastatic pancreatic cancer (Phase 3), Ovarian cancer (Phase 3).
At a glance
| Generic name | rondecabtagene autoleucel |
|---|---|
| Also known as | LYL314 |
| Sponsor | Lyell Immunopharma, Inc. |
| Drug class | CAR-T cell therapy |
| Target | Mesothelin (MSLN) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug involves ex vivo transduction of autologous T cells with a lentiviral vector encoding a CAR construct. The CAR-T cells are expanded and reinfused into the patient, where they recognize and eliminate tumor cells expressing the target antigen. This approach harnesses the patient's own immune system for durable anti-tumor activity.
Approved indications
- Metastatic pancreatic cancer (Phase 3)
- Ovarian cancer (Phase 3)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |